Table 1. Week 12 efficacy outcomes
| ADA (N=84) | PBO (N=81) | P valuea | |
|---|---|---|---|
| Primary endpointb | |||
| PSpARC 40, % | 39.3 | 19.8 | 0.006 |
| Secondary endpoints (mean change) | |||
| PGAc (VAS 0–100), mm | –27.5 | –16.4 | 0.003 |
| PGA painc (VAS 0–100), mm | –28.9 | –17.1 | 0.001 |
| PhGAc (VAS 0–100), mm | –32.2 | –18.2 | <0.001 |
| TJCc (0–78) | –5.9 | –1.8 | <0.001 |
| SJCc (0–76) | –3.6 | –3.1 | .045 |
| Leeds enthesitis indexc (0–6) | –0.8 | –0.1 | <0.001 |
| SPARCC enthesitis indexc (0–16) | –1.7 | –0.7 | <0.001 |
| Dactylitis countc (0–20) | –0.2 | –0.3 | 0.808 |
| BASDAIc | –2.1 | –1.0 | 0.003 |
| HAQ-S scorec | –0.3 | –0.2 | 0.051 |
| SF-36v2 PCSd | 6.7 | 2.4 | <0.001 |
aADA vs. PBO; bNRI; cLOCF; dObserved data (N=83/79, ADA/PBO).